MRK•benzinga•
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
Summary
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga